Dermatologie (Heidelberg, Germany)最新文献

[Nail psoriasis-painful and yet undertreated : From pathogenesis to therapy]. [指甲银屑病-疼痛但治疗不足：从发病机制到治疗]。

Dermatologie (Heidelberg, Germany) Pub Date : 2025-04-04 DOI: 10.1007/s00105-025-05495-z

Katharina Assaf, Marcel Georg Peter Irintchev, Dagmar Wilsmann-Theis

{"title":"[Nail psoriasis-painful and yet undertreated : From pathogenesis to therapy].","authors":"Katharina Assaf, Marcel Georg Peter Irintchev, Dagmar Wilsmann-Theis","doi":"10.1007/s00105-025-05495-z","DOIUrl":"https://doi.org/10.1007/s00105-025-05495-z","url":null,"abstract":"Nail psoriasis (NP) affects approximately 50% of psoriasis patients and is a common but often oversee disease feature that correlates with the duration and severity of psoriasis. The pathogenesis of NP is dominated by the increased expression of inflammatory cytokines such as interleukin (IL)-23 and IL-17, which leads to painful inflammation and hyperkeratosis in the nail apparatus. Clinically, there are changes to the nail matrix and the nail bed, usually characterized by spotty nails and distal onycholysis. In addition, psoriatic arthritis is more common in patients with NP. Patients with NP have a higher reduction in health-related quality of life and a higher comorbidity profile than psoriasis patients without NP. Various scores such as the Nail Psoriasis Severity Index (NAPSI) and the Physician's Global Assessment of Fingernail Psoriasis Score (f-PGA) or the Nail Assessment in Psoriasis and Psoriasis Arthritis (NAPPA) are available for the objective assessment of severity, whereby the latter also takes subjective symptoms into account. In terms of differential diagnosis, onychomycosis or its coexistence should always be considered when making the diagnosis. The severity-adapted treatment of NP is often extremely protracted. Overall, there are only a few studies on topical or systemic traditional therapy. Significantly more and promising data are available on the use of biologic therapies, which are often recommended for the primary treatment of NP, particularly in cases of nail matrix infestation.","PeriodicalId":72786,"journal":{"name":"Dermatologie (Heidelberg, Germany)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143782169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Nail cosmetics-risks and opportunities]. 【美甲化妆品——风险与机遇】

Dermatologie (Heidelberg, Germany) Pub Date : 2025-04-02 DOI: 10.1007/s00105-025-05498-w

Sophie Pompecki, Galina Balakirski, Christoph R Löser

引用次数: 0

[Cutaneous manifestations of sarcoidosis]. [结节病的皮肤表现]。

Dermatologie (Heidelberg, Germany) Pub Date : 2025-04-01 Epub Date: 2025-03-11 DOI: 10.1007/s00105-025-05491-3

Henning Klapproth, Torsten Kubacki, Mario Fabri, Esther von Stebut

引用次数: 0

[Systemic therapy of atopic dermatitis and psoriasis in children and adolescents]. [儿童和青少年特应性皮炎和银屑病的全身治疗]。

Dermatologie (Heidelberg, Germany) Pub Date : 2025-04-01 Epub Date: 2025-03-19 DOI: 10.1007/s00105-025-05486-0

Michael Sticherling

引用次数: 0

[Systemic treatments in pediatric and adolescent dermatology]. [儿童和青少年皮肤病的系统治疗]。

Dermatologie (Heidelberg, Germany) Pub Date : 2025-04-01 Epub Date: 2025-03-26 DOI: 10.1007/s00105-025-05487-z

Michael Sticherling, Kira Süßmuth

引用次数: 0

[Cutaneous leishmaniasis misdiagnosed as epithelial skin cancer]. 【皮肤利什曼病误诊为上皮性皮肤癌】。

Dermatologie (Heidelberg, Germany) Pub Date : 2025-04-01 Epub Date: 2025-02-05 DOI: 10.1007/s00105-025-05473-5

Ana-Lee Gerdes, Alexander Kreuter, Uwe Hillen, Jörg Schaller, Frank Oellig, Julia Hyun, Valentina Laura Müller

引用次数: 0

[Malignant or benign-pigmented neoplasm on the scalp]. [头皮上的恶性或良性色素瘤]。

Dermatologie (Heidelberg, Germany) Pub Date : 2025-04-01 Epub Date: 2025-03-06 DOI: 10.1007/s00105-025-05479-z

Barbara Salzmann, Ferdinand Toberer, Wolfgang Hartschuh

引用次数: 0

[Intralesional rituximab for refractory granuloma faciale]. [病灶内美罗华治疗难治性面部肉芽肿]。

Dermatologie (Heidelberg, Germany) Pub Date : 2025-04-01 Epub Date: 2025-02-03 DOI: 10.1007/s00105-025-05476-2

Lea Braun, Christoph Löser, Mindaugas Andrulis, Matthias Uhl, Manfred Wolter, Edgar Dippel

引用次数: 0

[Systemic therapies for pediatric patients with ichthyosis]. [儿童鱼鳞病患者的全身治疗]。

Dermatologie (Heidelberg, Germany) Pub Date : 2025-04-01 Epub Date: 2025-03-07 DOI: 10.1007/s00105-025-05484-2

Laura Trefzer, Kira Süßmuth

{"title":"[Systemic therapies for pediatric patients with ichthyosis].","authors":"Laura Trefzer, Kira Süßmuth","doi":"10.1007/s00105-025-05484-2","DOIUrl":"10.1007/s00105-025-05484-2","url":null,"abstract":"Background: Hereditary ichthyoses are rare, etiologically and clinically heterogeneous epidermal keratinization disorders that are characterized by excessive dryness with scaling of the skin and in some cases increased palmoplantar keratinization. Additional inflammation is common and there are forms associated with blistering. In terms of differential diagnosis, ichthyoses with associated erythroderma in particular must be distinguished from primary atopic diseases with immunodeficiency.Aim: The aim is to provide basic knowledge of the classification and nomenclature of ichthyoses and of current guideline-based and approved therapies. Readers should also be made aware of the difficulties of treating this rare skin disease in children and adolescents with only a few approved therapies. New and innovative treatment options are described and thereafter the reader should be able to confidently identify potential patients for approved and novel therapies.Materials and methods: The current guidelines as well as the current literature and expert consensus on systemic therapies for ichthyosis with a focus on pediatric patients are discussed.Results: Precise phenotyping, endotyping and the inclusion of the patient's expectations with regard to therapy currently allow comprehensive treatment to alleviate symptoms with good interdisciplinary cooperation. In the absence of causal therapy options, hereditary ichthyosis usually requires lifelong symptomatic individualized therapy. The basis of therapy is local therapy. Acitretin is currently the only approved systemic therapy. Pathophysiologically driven and therefore personalized and targeted therapies, in the form of topical replacement proteins or lipids, small molecules with a variety of target structures and biologics to address inflammation, are the focus of new therapeutic options. Causal therapeutic approaches, such as gene therapies, are currently under development.","PeriodicalId":72786,"journal":{"name":"Dermatologie (Heidelberg, Germany)","volume":" ","pages":"193-201"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[New-onset nail psoriasis after treatment with pembrolizumab and durvalumab]. [pembrolizumab和durvalumab治疗后新发指甲牛皮癣]。

Dermatologie (Heidelberg, Germany) Pub Date : 2025-04-01 DOI: 10.1007/s00105-025-05496-y

Asmaa Alwadi, Silke C Hofmann, Ulrich Wesselmann, Galina Balakirski

引用次数: 0